

SECURITIES AND EXCHANGE COMMISSION

FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2006-05-08** | Period of Report: **2006-05-08**
SEC Accession No. **0000950162-06-000526**

([HTML Version](#) on [secdatabase.com](#))

FILER

AMARIN CORP PLC\UK

CIK: **897448** | IRS No.: **000000000** | Fiscal Year End: **0831**
Type: **6-K** | Act: **34** | File No.: **000-21392** | Film No.: **06816380**
SIC: **2834** Pharmaceutical preparations

Business Address
GEMINI HOUSE
BARTHOLOMEWS WALK
CAMBRIDGESHIRE BUSINESS
PARK
ELY CAMBRIDGESHIRE C X0
00000

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of May, 2006

Commission File Number 0-21392

AMARIN CORPORATION PLC
(Translation of registrant's name into English)

7 Curzon Street, London W1J 5HG, England
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

No

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

No

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

EXHIBIT LIST

<u>Exhibit</u>	<u>Description</u>
----------------	--------------------

- | | |
|------|---|
| 99.1 | Press release dated May 8, 2006 titled:
Amarin to present at Rodman & Renshaw 3rd Annual Global Healthcare Conference. |
|------|---|
-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By: /s/ Richard A. B. Stewart

Richard A. B. Stewart
Chief Executive Officer

Date: May 8, 2006



AMARIN TO PRESENT AT RODMAN & RENSHAW 3rd ANNUAL GLOBAL HEALTHCARE CONFERENCE

LONDON, United Kingdom, May 8, 2006 - Amarin Corporation plc (NASDAQ: AMRN) today announced that Alan Cooke, Chief Financial Officer of Amarin, will present a corporate update at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15, 2006 at 3.00 p.m. Central European Time/2.00 p.m. British Summer Time/9.00 a.m. Eastern Standard Time. The conference will be held from May 15 to 16 at Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco.

The presentation will be simultaneously webcast and a link will be provided on Amarin Corporation's website www.amarincorp.com

About Amarin

Amarin is a neuroscience company focussed on the research, development and commercialization of novel drugs for the treatment of central nervous system disorders. Miraxion, Amarin's lead development compound, is in Phase III development for Huntington's disease, Phase II development for depressive disorders and preclinical development for Parkinson's disease. Miraxion for Huntington's disease is being developed under a Special Protocol Assessment agreed with the US Food and Drug Administration ("FDA"), has been granted fast track designation by the FDA and has received orphan drug designation in the US and Europe.

Contacts:

Amarin Corporation
plc
+44 (0) 207 907 2442

Rick Stewart
Alan Cooke

Chief Executive Officer
Chief Financial Officer

investor.relations@amarincorp.com

Investors:

Lippert/Heilshorn & Associates, Inc. +1 212 838 3777
Kim Golodetz (kgolodetz@lhai.com)
Anne Marie Fields (afields@lhai.com)

Media:

Powerscourt +44 (0) 207 236 5615
Rory Godson/Victoria Brough

For press releases and other corporate information, visit our website at <http://www.amarincorp.com>. Information on our website is not part of this press release.

The information contained in this document is as of May 8, 2006. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial risks

and uncertainties. You can identify these statements by the fact that they use words such as "will", "anticipate", "estimate", "project", "forecast", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or events. Among the factors that could cause actual results to differ materially from those described or projected herein are the following: the success of Amarin's research and development activities, including the phase III trials with Miraxion in Huntington's disease; decisions by regulatory authorities regarding whether and when to approve Amarin's drug applications, as well as their decisions regarding labeling and other matters that could affect the commercial potential of Amarin's products; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the success with which developed products may be commercialized; competitive developments affective Amarin's products under development; the effect of possible domestic and foreign legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including under Medicaid and Medicare in the United States, and involuntary approval of prescription medicines for over-the-counter use; Amarin's ability to protect its patents and other intellectual property; claims and concerns that may arise regarding the safety or efficacy of Amarin's product candidates; governmental laws and regulations affecting Amarin's operations, including those affecting taxation; Amarin's ability to maintain sufficient cash and other liquid resources to meet its operating requirements; general changes in U.K. and U.S. generally accepted accounting principles; growth in costs and expenses; and the impact of acquisitions, divestitures and other unusual items, including Amarin's ability to integrate its acquisition of Amarin Neuroscience Limited. A further list and description of these risks, uncertainties and other matters can be found in Amarin's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, and in its Reports of Foreign Issuer on Form 6-K furnished to the SEC.